Global anti-obesity prescription drugs market is expected to witness a staggering CAGR in the forecast period. Anti-obesity drugs are pharmacological agents that are used to drop cholesterol level and condense the body weight. These drugs are normally well-known for their action that can alter the important functioning of the normal body by utilizing the calories or by changing the appetite.
The growth of anti-obesity prescription drugs market is tremendously influenced because of the food consumptions and eating patterns of the masses has endured groundbreaking variations over the past decade. The liking of the youth for junk food has regulated in a higher incidence of obesity, which is increasing the demand for anti-obesity prescription drugs. There is a usage of cholesterol-rich products in the food items that are prepared in the restaurants, and this cooking method is now shifting to houses. This is playing a devious role in the progress of the anti-obesity prescription drug market in the existing development.
In addition to this, there is an upsurge in the level of chronic stress and rise in the consumption of alcoholic beverages will be continued by the consumers and this will expand the demand for anti-obesity prescription drugs. Also, there have been growing incidences of depression; which is leading to more intake of the psychotropic drugs and the side effects of these drugs leads to obesity. Looking at the ultramodern aspect, the existing as well new investors have started investing in this market, which will appeal the manufacturers and this will eventually lead to more effective anti-obesity prescription drugs. These are some of the major dynamics that will help the anti-obesity prescription drug market to experience massive growth during the forecast period.
The market is segmented on the basis of drug class (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide); by age group (pediatric, adult); by end user (e-commerce, retail pharmacies, and hospital pharmacies) and by geography (North America, Europe, Latin America, Middle East & Africa, and Asia Pacific).
Geographically, North America is surging and holds the largest market share as the demand for weight loss/control drugs is increasing in this region is predicted to register an extensive growth rate during the estimated time span. Followed by this, Europe is anticipated to experience substantial growth prospects in the forthcoming years. Along with this, Asia Pacific is expected to foresee decent growth during the forecast period. In the near future, the market will continue to come up with some extraordinary product innovations to attract new consumers and investors, for them to continue the domination.
Some of the significant key players outlined in the anti-obesity prescription drugs market report are GlaxoSmithKline, VIVUS, Inc, F Hoffmann La Roche Ltd., Arena Pharmaceuticals, Inc., Alizyme, Orexigen Therapeutics, Inc., Boehringer Ingelheim and Novo Nordisk A/S. All the leading companies are including mergers and acquisitions, partnerships and joint ventures to enhance the growth of the market efficiently.
Leading players of Anti-Obesity Prescription Drugs including:
• F Hoffmann La Roche
• Arena Pharmaceuticals
• Orexigen Therapeutics
• Phentermine and Topiramate
• VIVUS, Inc
• Bupropion and Naltrexone
• Bupropion and Naltrexone
• Novo Nordisk
Market split by Type, can be divided into:
• Oral Medicine
• Diet Patch
Market split by Application, can be divided into:
• Hospitals Pharmacies
• Retail Pharmacies
Market split by Sales Channel, can be divided into:
• Direct Channel
• Distribution Channel
Market segment by Region/Country including:
• North America (United States, Canada and Mexico)
• Europe (Germany, UK, France, Italy, Russia and Spain etc.)
• Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
• South America Brazil, Argentina, Colombia and Chile etc.)
• Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)
Research Support Specialist, USA